A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3 ; P06124).

Trial Profile

A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3 ; P06124).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Asenapine (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 25 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 27 Mar 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2014 to 1 Apr 2014.
    • 27 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top